supp.fit

Fish Oil and Omega-3 Fatty Acids: study protocols

99 study groups took Fish Oil together with Omega-3 Fatty Acids. These are the doses the studies gave. They are not a recommendation.

Fish Oil: what the research found →

Dose per serving from research: Fish Oil

89 study groups in 76 studies say how much Fish Oil participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g and 2.5 g to 5 g, 29% of 89 study groups each.

Daily doseStudy groups
500 mg or less
4
500 mg to 1 g
15
1 g to 2.5 g
26
2.5 g to 5 g
26
5 g to 10 g
15
over 10 g
3

Dose per serving from research: Omega-3 Fatty Acids

95 study groups in 82 studies say how much Omega-3 Fatty Acids participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 1 g to 2.5 g, 38% of 95 study groups.

Daily doseStudy groups
250 mg or less
5
250 mg to 500 mg
6
500 mg to 1 g
20
1 g to 2.5 g
36
2.5 g to 5 g
28

Commonly used together

50 of 99 study groups took Fish Oil and Omega-3 Fatty Acids with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Docosahexaenoic Acid
41
Vitamin E
6
EPA
4
Vitamin D
3

99 study groups

Study
Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL
2025 · omega-3 FA supplementation arm · US men aged 50 years or older and women aged 55 years or older in a primary-prevention trial
1 g840 mg5 years12,933
The impact of pre- and postnatal exposures on allergy related diseases in childhood: a controlled multicentre intervention study in primary health care
2013 · intervention cohort · Pregnant women and their children in the general population of Trondheim; no age range or sex restriction stated
5 mL1.2 g—1,374
Fish oil intake compared with olive oil intake in late pregnancy and asthma in the offspring: 16 y of registry-based follow-up from a randomized controlled trial
2008 · fish oil · Women with normal pregnancies, recruited around gestation week 30
4 g2.7 g—266
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
2019 · n-3 fatty acids group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial
1 g840 mg1936 days—
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial
1 g840 mg1936 days—
Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial
2023 · Multidomain plus omega 3 · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed
400 mg400 mg3 years129
Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial
2023 · Omega 3 alone · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed
400 mg400 mg3 years112
Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development
2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required
2 mL300 mg26 weeks87
Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)
2023 · MAG-EPA intervention group · Adult men with aggressive localized prostate cancer (Gleason score ≥ 7, ISUP Grade group ≥ 2) treated by radical prostatectomy
3.75 g3.3 g1 year65
Untitled
2012 · omega-3 PUFA · Healthy adults aged 51–72 years, women and men, with BMI 20–30 kg/m² and no known metabolic disease or cognitive decline
5 g3 g5 weeks38
A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine
2024 · EPA group · Adults with episodic migraine; age and sex range not reported
2 g1.8 g12 weeks35
Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome
2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation
10 mL242 mg/kg1 year33
Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial
2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day
5 g900 mg90 days27
Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial
2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder
1.35 g2.13 g12 weeks27
Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus
2015 · fish oil · Adults aged 18–64 with systemic lupus erythematosus
2.25 g4.5 g26 weeks25
Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial
2020 · TG1 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis
3 g900 mg60 days25
Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial
2020 · TG2 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis
3 g900 mg60 days25
The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery
2 g940 mg30 days18
[Polyunsaturated omega-3 fatty acids in the treatment of experimental human gingivitis]
1996 · treatment group · Healthy volunteers; age and sex not specified; no stated condition
6 g1.8 g7 days18
Pilot study on n-3 polyunsaturated fatty acids in the treatment of human experimental gingivitis
1997 · drug (fish oil) group · Healthy volunteers with experimentally induced gingivitis; age and sex not stated
6 g1.8 g8 days18
Fish oil supplemented for 9 months does not improve glycaemic control or insulin sensitivity in subjects with impaired glucose regulation: a parallel randomised controlled trial
2016 · Fish oil (FO) · Adults with impaired glucose regulation; age and sex not reported
6 g3.9 g270 days16
Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment
2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified
2.4 g1.6 g24 weeks15
Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial
2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis
1 g300 mg90 days15
Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females
2015 · fish oil (FO) · Community-dwelling females aged 60–76 years in generally good health, with low fish intake and no omega-3 supplement use
5 g3 g12 weeks12
Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial
2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition
2.4 g600 mg62 days12
Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults
2020 · Fish oil group · Healthy physically active men and women aged 60–75 years
5 g2 g12 weeks12
Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions
2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition
2.4 g600 mg62 days10
The effect of fish oil supplementation on resistance training-induced adaptations
2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease
4.5 g2.28 g10 weeks10
Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance
2025 · Omega-3 + USRPT (OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition
1 g680 mg8 weeks10
Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors
2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training
2.4 g600 mg62 days8
Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes
2003 · n-3 PUFA diet · Elite athletes, including athletes with exercise-induced bronchoconstriction (EIB) and athletes without EIB; age and sex not reported
3.2 g—3 weeks5
Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids
2001 · dietary n-3FA therapy · Patients with sickle cell disease; age and sex not stated
250 mg/kg100 mg/kg30 days—
Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial
1992 · fish oil · Patients with ulcerative colitis, including patients entering in relapse and patients in remission
20 mL4.5 g1 year—
Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers
2007 · fish oil supplementation · Healthy men aged 26.0 ± 3.1 years
7.2 g1.8 g4 weeks—
Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study
2007 · fish oil group · Women with type 2 diabetes without hypertriglyceridemia
3 g1.8 g60 days—
The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study
2011 · drug group · Adults aged 65 years or older with mild to moderate depression
1 g300 mg26 weeks—
Fish oil supplementation improves neutrophil function during cancer chemotherapy
2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated
2 g300 mg8 weeks—
Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study
1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported
1.71 g1.71 g1 year—
Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis
1993 · fish-oil group · Patients with moderate-to-severe psoriasis; age and sex not specified
6 g5 g120 days—
The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial
2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition
2 g1 g18 weeks134
Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis
2 g1.42 g12 weeks40
Lipid Profile, Lipoprotein Subfractions, and Fluidity of Membranes in Children and Adolescents with Depressive Disorder: Effect of Omega-3 Fatty Acids in a Double-Blind Randomized Controlled Study
2020 · Om3 group · Children and adolescents aged 11–17 years with depressive disorder or mixed anxiety and depressive disorder
20 mL4.15 g12 weeks29
Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children
2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis
2 g600 mg120 days26
Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial
2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis
20 mL2.6 g26 weeks24
Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial
2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis
20 mL2.6 g90 days20
An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553]
2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress
2 g120 mg6 weeks16
Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance
2025 · Probiotics + Omega-3 + USRPT (PRO + OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition
1 g680 mg8 weeks10
Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients
1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported
216 mg216 mg6 weeks—
Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial
2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms
706 mg706 mg90 days—
Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation
2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²)
3 g1.95 g16 weeks—
Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation
2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²)
3 g1.95 g16 weeks—
Evaluating the Impact of Omega-3 Fatty Acid (Soloways(TM)) Supplementation on Lipid Profiles in Adults with PPARG Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial
2023 · omega-3 fatty acids group · Adults aged 40–75 with LDL-C levels of 70–190 mg/dL and low-to-moderate cardiovascular risk, including participants with and without PPARG polymorphisms
2 g1.8 g90 days51
Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study
2018 · FO concentrate · Obese men and women with BMI >30
4 g1.6 g12 weeks12
Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis
2016 · Fish oil providing 0.7 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31.
700 mg700 mg8 weeks—
Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis
2016 · Fish oil providing 1.8 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31.
1.8 g1.8 g8 weeks—
Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial
2018 · ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported
6 g3.65 g12 weeks—
Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial
2018 · LCHP+ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported
6 g3.65 g12 weeks—
Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the Trials of Hypertension Prevention
1994 · fish oil group · Normotensive men and women aged 30–54 years
6 g3 g26 weeks—
Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol
2017 · Omega3Q10 treatment group · Adults aged at least 50 years with elevated blood pressure and/or elevated blood cholesterol
1 g514 mg12 weeks48
Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects
2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia
9.6 g1.7 g4 weeks21
Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration: A randomized, double-blind, crossover study
2023 · phospholipid-enhanced fish oil (PEFO) · Healthy adult men and women
1 g—1 day24
Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease
1995 · fish-oil group · Patients with coronary artery disease; age range and sex not stated
4 g3.4 g39 weeks260
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes
3.36 g1.86 g1 year147
Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported
1 g650 mg1 year50
Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements
2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication
4.4 g4.4 g30 days40
A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial
2019 · Omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation
2 g1.4 g12 weeks35
Effect of chia seeds or concentrated fish oil on cardiometabolic risk markers in subjects with hypertriglyceridaemia: a parallel clinical trial
2024 · low-calorie diet with concentrated fish oil · Patients with hypertriglyceridaemia; age and sex not specified
1.8 g1.8 g8 weeks22
Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome
2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m²
2.15 g2.15 g6 weeks21
Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men
2014 · LC n-3 PUFA supplementation · Men aged 24–48 years: 10 normolipidemic and 10 with mild combined hyperlipidemia
5.04 g2.52 g12 weeks20
Effects of Long Chain Omega-3 Polyunsaturated Fatty Acids on Brain Function in Mildly Hypertensive Older Adults
2018 · LCn-3PUFA group · Adults aged 40–85 with borderline or mild hypertension and low fish/seafood intake
1.6 g2 g20 weeks19
Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial
2012 · oxidised fish oil · Healthy adults aged 18–50 years
8 g1.6 g7 weeks18
Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial
2012 · fish oil · Healthy adults aged 18–50 years
8 g1.6 g7 weeks17
Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach
2014 · FO group · Healthy men and women aged 18–50 years
8 g700 mg7 weeks17
Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial
2019 · FO (fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women
2 g1.2 g12 weeks17
Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial
2019 · CC-FO (curcumin plus fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women
2 g1.2 g12 weeks16
Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial
2025 · EPA-rich fish oil · Adults aged 18–65 with non-severe burns covering less than 20% of total body surface area
1.5 g2.1 g3 weeks12
Effect of 21-Day Omega-3 Polyunsaturated Fatty Acid Supplementation on Exercise-Induced Secretory Factors and Inflammation Status in Young Men: A Randomized Double-Blind Trial
2026 · supplementation group · Physically active, healthy men aged approximately 22 years
5 g3.25 g3 weeks12
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication
4.4 g4.4 g90 days11
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication
4.4 g4.4 g90 days11
n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes
2016 · n-3 PUFA (fish oil) supplementation · Men with type 2 diabetes; mean age 54.7 ± 7.6 years
5 g3 g8 weeks10
Effect of dietary n-3 PUFA supplementation on the muscle transcriptome in older adults
2016 · n-3 PUFA group · Healthy men and women aged 60–85 years
4 g3.36 g26 weeks10
Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study
1996 · Fish oil (FO) · Patients with hyperlipidemic non-insulin-dependent diabetes mellitus; age and sex not reported
22 mL4.6 g2 weeks10
Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study
1994 · fish oil group · Adults with non-insulin-dependent diabetes mellitus (NIDDM)
5 g2.5 g6 weeks9
Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics
1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract
4 g1.4 g12 days—
Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion
1999 · fish oil supplement group · Human volunteers; age, sex, and health status not specified
20 mL3.6 g15 days—
Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions
2000 · fish oil (FO) · Healthy subjects; age and sex not specified
9 g2.1 g12 weeks—
Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study
2004 · n-3 PUFA group · Healthy adult males
12 g4 g8 weeks—
Treatment for 6 months with fish oil-derived n-3 polyunsaturated fatty acids has neutral effects on glycemic control but improves dyslipidemia in type 2 diabetic patients with abdominal obesity: a randomized, double-blind, placebo-controlled trial
2017 · fish oil group · Adults with type 2 diabetes and abdominal obesity; mean age 65.4 years; 35 men and 64 women completed the study
4 g2.4 g26 weeks—
Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects
2020 · Saury oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease
12 g3.4 g8 weeks—
Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects
2020 · Control oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease
12 g3 g8 weeks—
Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial
2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications
3 g1.1 g12 weeks—
A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial
2019 · PS plus omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation
2 g1.4 g12 weeks41
The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial
2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program
6 g3.6 g4 weeks11
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration
2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment
1.05 g1.05 g—10
Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects
2009 · fish oil capsules · Hypertriglyceridaemic volunteers recruited from the Wollongong community; age and sex not reported
1 g1.05 g6 weeks—
Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial
2022 · Active treatment group · Adults aged 65–80 with low-grade inflammation (hs-CRP 1.5–6 mg/L) and BMI 18.5–27 kg/m²
1.1 g640 mg8 weeks—
Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study
2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP
180 mg180 mg4 weeks—
Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study
2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed
800 mg225 mg3 years401
Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study
2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed
800 mg225 mg3 years399